Piramal Pharma expects a recovery in FY27 with mid-teens revenue growth and improved margins, supported by CDMO rebound, stronger order inflows, and global supply chain shifts
​Piramal Pharma expects a recovery in FY27 with mid-teens revenue growth and improved margins, supported by CDMO rebound, stronger order inflows, and global supply chain shifts by Soban News (international And National News)
